Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 15, Issue 2, 2009, Pages 199-205

  Ashorn, Sara ^a   Honkanen, Teemu ^a   Kolho, Kaija Leena ^b   Ashorn, Merja ^a,c   Välineva, Tuuli ^d   Wei, Bo ^e   Braun, Jonathan ^e   Rantala, Immo ^a   Luukkaala, Tiina ^c   Iltanen, Sari ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d UNIVERSITY OF TAMPERE   (Finland)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calprotectin; Crohn's disease; I2; Microbial antigens; OmpW; Ulcerative colitis

Indexed keywords

BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; CALGRANULIN; IMMUNOGLOBULIN A; OUTER MEMBRANE PROTEIN;

ADOLESCENT; ADULT; ARTICLE; BACTEROIDES; BLOOD ANALYSIS; CHILD; CLINICAL PRACTICE; CONTROLLED STUDY; CROHN DISEASE; DISEASE MARKER; EARLY DIAGNOSIS; ENTERITIS; FECES ANALYSIS; FEMALE; GASTROINTESTINAL ENDOSCOPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; PREDICTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PSEUDOMONAS FLUORESCENS; SACCHAROMYCES CEREVISIAE; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; FECES; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; SENSITIVITY AND SPECIFICITY;

EID: 66049137260     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20535     Document Type: Article

References (42)

1. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50-54.
2. Tibble JA, Sighthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology. 2000;119:15-22.
3. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a non-invasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14-22.
4. Aadland E, Fagerhol MK. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol. 2002;14: 823-825.
5. Olafsdottir E, Aksnes L, Fluge G, et al. Faecal calprotectin levels in infants with infantile colic, healthy infants, children with inflammatory bowel disease, children with recurrent abdominal pain and healthy children. Acta Paediatr. 2002;91:45-50.
6. Wassell J, Dolwani S, Metzner M, et al. Faecal calprotectin: a new marker for Crohn's disease? Ann Clin Biochem. 2004;41:230-232.
7. Angriman I, Scarpa M, D'Inca R, et al. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin Chim Acta. 2007;381:63-68.
8. McKenzie H, Main J, Pennington CR, et al. Antibody to selected strains of Saccharomyces cerevisiae (baker's and brewer's yeast) and Candida albicans in Crohn's disease. Gut. 1990;31:536-538.
9. Vasiliauskas EA, Kam LY, Karp LC, et al. Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics. Gut. 2000;47:487-496.
10. Dubinsky MC, Ofman JJ, Urman M, et al. Clinical utility of serodiagnostic testing in suspected pediatric inflammatory bowel disease. Am J Gastroenterol. 2001;96:758-765.
11. Bartunkova J, Kolarova I, Sediva A, et al. Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cervisie antibodies, and specific IgE to food allergens in children with inflammatory bowel disease. Clin Immunol. 2002;102:162-168.
12. Reese GE, Constantinides VA, Simillis C, et al. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol. 2006;101:2410-2422.
13. Desplat-Jego S, Johanet C, Escande A, et al. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases: results of a multicenter study. World J Gastroenterol. 2007;13:2312-2318.
14. Saxon A, Shanahan F, Landers CJ, et al. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel disease. J Allergy Clin Immunol. 1990;86:202-210.
15. Cohavy O, Harth G, Horwitz M, et al. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect Immun. 1999;67:6510-6517.
16. Cohavy O, Bruckner D, Gordon LK, et al. Colonic bacteria express an ulcerative colitis pANCA-related protein epitope. Infect Immun. 2000; 68:1542-1548.
17. Israeli E, Grotto I, Gilburd B, et al. Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 2005;54:1232-1236.
18. Sendid B, Quinton JF, Charrier G, et al. Anti-Saccharomyces cerevisiae mannan antibodies in familial Crohn's disease. Am J Gastroenterol. 198;93:1306-1310.
19. Vermeire S, Peeters M, Vlietinck R et al. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD families. Inflamm Bowel Dis. 2001;7:8-15.
20. Sutton CL, Kim J, Yamane A, et al. Identification of a novel bacterial sequence associated with Crohn's disease. Gastroenterology. 2000;119: 23-31.
21. Wei B, Huang T, Dalwadi H, et al. Pseudomonas fluorescens encodes the Crohn's disease-associated I2 sequence and T-cell superantigen. Infect Immunol. 2002;70:6567-6575.
22. Wei B, Dalwadi H, Gordon LK, et al. Molecular cloning of a Bacteroides caccae TonB-linked outer membrane protein identified by an inflammatory bowel disease marker antibody. Infect Immun. 2001;69: 6044-6054.
23. Landers CJ, Cohavy O, Misra R, et al. Selected loss of tolerance evidenced by Crohn's disease-associated immune responses to auto- and microbial antigens. Gastroenterology. 2002;123:689-699.
24. Zholudev A, Zurakowski D, Young W, et al. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Am J Gastroenterol. 2004;99:2235-2241.
25. Jaskowski TD, Litwin CM, Hill HR. Analysis of serum antibodies in patients suspected of having inflammatory bowel disease. Clin Vaccine Immunol. 2006;13:655-660.
26. Iltanen S, Tervo L, Halttunen T, et al. Elevated serum anti-I2 and anti-OmpW antibody levels in children with IBD. Inflamm Bowel Dis. 2006;12:389-394.
27. Arnott ID, Landers CJ, Nimmo EJ, et al. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am J Gastroenterol. 2004;99:2376-2384.
28. Evans CM, Beattie RM, Walker-Smith JA. Inflammatory bowel disease in childhood. In: Allan RN, Rhodes JM, Hanauer SB, eds. Inflammatory Bowel Diseases. 3rd ed. New York: Churchill Livingstone; 1997:647-670.
29. Dixon FM, Genta RM, Yardley JH, et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996;20: 1161-1181.
30. Kolho KL, Raivio T, Lindahl H, et al. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol. 2006;41:720 -725.
31. Amati L, Passeri ME, Selicato F, et al. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease. Immunopharmacol Immunotoxicol. 2006;28:665- 681.
32. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol. 2007;102:803-813
33. Riis L, Vind I, Vermeire S, et al. The prevalence of genetic and serologic markers in an unselected European population-based cohort of IBD patients. Inflamm Bowel Dis. 2007;13:24-32.
34. Papp M, Norman GL, Altorjay I, et al. Utility of serological markers in inflammatory bowel diseases: gadget or magic? World J Gastroenterol. 2007;13:2028-2036.
35. Melmed GY, Elashoff R, Chen GC, et al. Predicting a change in diagnosis from ulcerative colitis to Crohn's disease: a nested, case-control study. Clin Gastroenterol Hepatol. 2007;5:602-608.
36. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol. 2006;101:360-367.
37. Lodes MJ, Conf. Y, Elson CO, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest. 2004;113:1296-1306.
38. Targan SR, Landers CJ, Yang H, et al. Antibodies to Cbir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology.. 2005; 128:2020-2028.
39. Bossuyt X. Serologic markers in inflammatory bowel disease. Clin Chem. 2006;52:171-181.
40. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology. 2004;126:414-424.
41. Ferrante M, Henckaerts L, Joossens M, et al. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut. 2007;56:1394-1403.
42. Forcione DG, Rosen MJ, Kisiel JB, et al. Anti-Saccaharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for surgery. Gut. 2004;53:1117-1122.